T细胞炎症基因表达谱、程序性死亡配体1表达与肿瘤突变负荷预测帕博利珠单抗在20种癌症患者中的疗效:KEYNOTE-028研究
KEYNOTE-028是一项非随机Ib期试验,纳入475例PD-L1阳性晚期实体瘤患者,接受帕博利珠单抗10 mg/kg每2周治疗2年或至确认疾病进展或不可接受毒性。客观缓解率从胰腺癌的0%(95%CI 0.0%至14.2%)到小细胞肺癌的33%(95%CI 15.6%至55.3%)。T细胞炎症基因表达谱、PD-L1表达和肿瘤突变负荷较高的肿瘤显示出更高的缓解率和更长的无进展生存期。
要点
- 在20种晚期实体瘤中,客观缓解率范围为0%至33%,胰腺癌最低,小细胞肺癌最高。
- T细胞炎症基因表达谱、PD-L1表达和/或肿瘤突变负荷较高的肿瘤缓解率更高、无进展生存期更长。
- 肿瘤突变负荷与基因表达谱及PD-L1的相关性低;同时具有高肿瘤突变负荷和高炎症标志物(基因表达谱或PD-L1)的患者缓解可能性最高。
核心结论
- T细胞炎症基因表达谱、PD-L1表达和肿瘤突变负荷可预测多种肿瘤类型对帕博利珠单抗的缓解。
- 这些生物标志物(单独或联合)可能有助于识别在广谱癌症中对anti-PD-1治疗有较高缓解可能性的患者。
研究设计与样本
- KEYNOTE-028(ClinicalTrials.gov标识符:NCT02054806)是一项非随机Ib期试验,纳入475例PD-L1阳性晚期实体瘤患者。
- 患者接受帕博利珠单抗10 mg/kg每2周治疗2年或直至确认疾病进展或发生不可接受毒性。
- 主要终点为客观缓解率(按RECIST v1.1、研究者评估);次要终点包括安全性、无进展生存期和总生存期;T细胞炎症基因表达谱、PD-L1表达和肿瘤突变负荷与抗肿瘤活性的关系为探索性终点。
主要发现
- 客观缓解率(含95%CI)从胰腺癌的0%(0.0%至14.2%)到小细胞肺癌的33%(15.6%至55.3%)。
- 各队列中位无进展生存期(95%CI)从胰腺癌的1.7个月(1.5至2.9个月)到甲状腺癌的6.8个月(1.9至14.1个月)。
- 中位总生存期(95%CI)从外阴癌的3.9个月(2.8至5.5个月)到类癌肿瘤的21.1个月(9.1至22.4个月)。
- T细胞炎症基因表达谱、PD-L1表达和/或肿瘤突变负荷较高的肿瘤显示出更高的缓解率和更长的无进展生存期。
- 肿瘤突变负荷与基因表达谱及PD-L1的相关性低;同时具有高肿瘤突变负荷和高炎症标志物(基因表达谱或PD-L1)的患者缓解可能性最高。
关键数值与推荐
- 客观缓解率范围:胰腺癌0%(95%CI 0.0%至14.2%)至小细胞肺癌33%(95%CI 15.6%至55.3%)。
- 中位无进展生存期范围:胰腺癌1.7个月(95%CI 1.5至2.9个月)至甲状腺癌6.8个月(95%CI 1.9至14.1个月)。
- 中位总生存期范围:外阴癌3.9个月(95%CI 2.8至5.5个月)至类癌肿瘤21.1个月(95%CI 9.1至22.4个月)。
- 安全性与此前帕博利珠单抗报告相似且一致。
临床怎么用
- T细胞炎症基因表达谱、PD-L1表达和肿瘤突变负荷(单独或联合)可能有助于识别对anti-PD-1治疗有较高缓解可能性的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Biomarkers that can predict response to anti-programmed cell death 1 (PD-1) therapy across multiple tumor types include a T-cell-inflamed gene-expression profile (GEP), programmed death ligand 1 (PD-L1) expression, and tumor mutational burden (TMB). Associations between these biomarkers and the clinical efficacy of pembrolizumab were evaluated in a clinical trial that encompassed 20 cohorts of patients with advanced solid tumors. METHODS: KEYNOTE-028 ( ClinicalTrials.gov identifier: NCT02054806) is a nonrandomized, phase Ib trial that enrolled 475 patients with PD-L1-positive advanced solid tumors who were treated with pembrolizumab 10 mg/kg every 2 weeks for 2 years or until confirmed disease progression or unacceptable toxicity occurred. The primary end point was objective response rate (ORR; by RECIST v1.1, investigator review). Secondary end points included safety, progression-free survival (PFS), and overall survival (OS). Relationships between T-cell-inflamed GEP, PD-L1 expression, and TMB and antitumor activity were exploratory end points. RESULTS: ORRs (with 95% CIs) ranged from 0% (0.0% to 14.2%) in pancreatic cancer to 33% (15.6% to 55.3%) in small-cell lung cancer. Across cohorts, median (95% CI) PFS ranged from 1.7 months (1.5 to 2.9 months) to 6.8 months (1.9 to 14.1 months) in pancreatic and thyroid cancers, respectively, and median OS from 3.9 months (2.8 to 5.5 months) to 21.1 months (9.1 to 22.4 months) in vulvar and carcinoid tumors, respectively. Higher response rates and longer PFS were demonstrated in tumors with higher T-cell-inflamed GEP, PD-L1 expression, and/or TMB. Correlations of TMB with GEP and PD-L1 were low. Response patterns indicate that patients with tumors that had high levels of both TMB and inflammatory markers (GEP or PD-L1) represent a population with the highest likelihood of response. Safety was similar and consistent with prior pembrolizumab reports. CONCLUSION: A T-cell--inflamed GEP, PD-L1 expression, and TMB predicted response to pembrolizumab in multiple tumor types. These biomarkers (alone/in combination) may help identify patients who have a higher likelihood of response to anti-PD-1 therapies across a broad spectrum of cancers.
引用
- Ott PA, Bang YJ, Piha-Paul SA, et al. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. J Clin Oncol. 2018. PMID: 30557521. doi:10.1200/JCO.2018.78.2276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。